SEC Comment Letter for Advaxis, Inc. (ADXS) (CIK 0001100397) — Sep 2, 2021
Advaxis, Inc. (ADXS) (CIK 0001100397)
Date: Sept. 2, 2021 · CIK: 0001100397 · Accession: 0000000000-21-010714
AI Filing Summary & Sentiment
File numbers found in text: 333-259065
Letter
United States securities and exchange commission logo September 2, 2021 Kenneth A. Berlin President and Chief Executive Officer Advaxis, Inc. 9 Deer Park Drive, Suite K-1 Monmouth Junction, NJ 08852 Re:Advaxis, Inc. Registration Statement on Form S-4 Filed August 25, 2021 File No. 333-259065 Dear Mr. Berlin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact David Gessert at 202-551-2326 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
United States securities and exchange commission logo
September 2, 2021
Kenneth A. Berlin
President and Chief Executive Officer
Advaxis, Inc.
9 Deer Park Drive, Suite K-1
Monmouth Junction, NJ 08852
Re:Advaxis, Inc.
Registration Statement on Form S-4
Filed August 25, 2021
File No. 333-259065
Dear Mr. Berlin:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact David Gessert at 202-551-2326 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences